Scottish Enterprise

Mask Logic is a manufacturer of personalized protective gear specializing in respirators designed for safety and comfort. The company focuses on creating masks that offer respiratory protection, aiming to enhance health and safety in various workplace environments. By providing effective barriers against airborne health hazards, Mask Logic enables users to work with reduced risk of exposure to harmful particles, thus prioritizing the well-being of individuals in diverse settings.

Cytomos Limited is a biotechnology company based in Edinburgh, United Kingdom, that specializes in developing advanced cell sorting devices for laboratory research and clinical diagnostics. Founded in 2011, the company utilizes its patented Dielectric Spectroscopy (CDS) technology to enable label-free cell analysis, providing detailed insights at single-cell resolution. This technology supports various applications in biopharma and cell therapy by facilitating automated, quantitative assessments of samples and enhancing phenotypic drug discovery. Cytomos’ system is designed to scale across all upstream production stages, leveraging machine learning algorithms to analyze extensive data from individual cells, thus improving the efficiency of cell-based diagnostics and enabling researchers to optimize therapeutic dosing.

Neuranics is a company focused on developing advanced magnetic sensors integrated with semiconductor technology for applications in health, fitness, and the metaverse. Their proprietary technology is designed to detect minute magnetic impulses produced by the body's organs, utilizing scalable spintronics sensors. This innovative approach aims to address the limitations of current health monitoring devices and enhance human-machine interfaces. By leveraging magnetic sensing, Neuranics seeks to improve the interaction with the central, peripheral, and autonomic nervous systems, as well as muscles, thereby offering significant advancements for healthcare companies in creating next-generation wearable and implantable devices.

Chromacity Ltd. is a company based in Edinburgh, United Kingdom, that specializes in the development, manufacture, and distribution of wavelength tunable femtosecond lasers for various applications in life sciences and spectroscopy. The company's product lineup includes several advanced laser systems, such as the Spark 1030-nm and Spark-HP 1040-nm femtosecond lasers, which are designed for high performance and versatility. Additionally, Chromacity offers femtosecond optical parametric oscillators (OPOs), such as the Spark-OPO and Spark-ultra, which produce tunable femtosecond pulses across a broad range of wavelengths. The technology is built on robust, patent-pending fiber-laser innovations, providing reliable and user-friendly operation through an embedded web server. Chromacity also collaborates with systems manufacturers to supply custom OEM femtosecond and picosecond lasers tailored to specific engineering and materials processing needs. Founded in 2013 as a spin-out from Heriot-Watt University, the company leverages over 40 years of expertise in ultrafast lasers and serves clients in North America, the United Kingdom, the Middle East, and beyond.

Nebu-Flow is a manufacturer focused on developing advanced inhaled drug delivery systems for patients with respiratory disorders. The company specializes in innovative technology that controls droplet size to enhance deep lung deposition, facilitating effective drug delivery through inhalation. This technology not only targets existing formulations but also accommodates emerging therapeutics, including biologics, nanomedicines, and vaccines. By enabling injection-free systemic drug delivery, Nebu-Flow aims to improve treatment options for various respiratory, cardiovascular, and central nervous system conditions. The company is also dedicated to minimizing its environmental impact while ensuring its nebulizers remain user-friendly and high-performing.

Microplate Dx is a developer of diagnostic technology focused on reducing fatalities from drug-resistant infections. As an award-winning spinout from the University of Strathclyde in Glasgow, the company aims to address the global health challenge of antimicrobial resistance. Microplate Dx's innovative solutions utilize highly sensitive biosensor electrodes, combined with miniaturized hydrogel deposits containing antibiotics specific to the infection being detected. Their medical diagnostic device provides a low-cost and accurate point-of-care alternative, enabling rapid antibiotic prescribing in under one hour. This approach enhances antibiotic stewardship and strives to manage the spread of antimicrobial resistance effectively.

Cytomos Limited is a biotechnology company based in Edinburgh, United Kingdom, that specializes in developing advanced cell sorting devices for laboratory research and clinical diagnostics. Founded in 2011, the company utilizes its patented Dielectric Spectroscopy (CDS) technology to enable label-free cell analysis, providing detailed insights at single-cell resolution. This technology supports various applications in biopharma and cell therapy by facilitating automated, quantitative assessments of samples and enhancing phenotypic drug discovery. Cytomos’ system is designed to scale across all upstream production stages, leveraging machine learning algorithms to analyze extensive data from individual cells, thus improving the efficiency of cell-based diagnostics and enabling researchers to optimize therapeutic dosing.

Merck KGaA, founded in 1668 in Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company, operating primarily in Europe, Africa, Asia, Oceania, and Latin America. The company is structured into several divisions, including Healthcare, Life Science, and Performance Materials, offering a range of products from over-the-counter medications to advanced materials for semiconductors. Merck KGaA also fosters innovation through its global network, including an innovation hub in Shanghai that collaborates with startups, academic institutions, and local governments to develop new technologies tailored to the Chinese market. In North America, the company operates as EMD Millipore, providing life science tools and solutions. The company maintains a strong commitment to enhancing healthcare and improving lives globally through its diverse product offerings and dedication to research and development.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.

Waire Health specializes in the development of wearable vital sign monitoring devices aimed at identifying high-risk patients in hospital wards and at home. By employing advanced artificial intelligence, the company's technology continuously monitors vital signs to detect patterns that may indicate the onset of conditions such as sepsis. This proactive monitoring allows clinicians to receive timely information, facilitating early intervention and improving patient outcomes. By operating autonomously, Waire's solutions help reduce healthcare costs while enhancing the quality of care for patients.

CardioPrecision created a ground-breaking, multiple-patent technology that enables medical professionals to do minimally invasive procedures using very little neck access.

Cytomos Limited is a biotechnology company based in Edinburgh, United Kingdom, that specializes in developing advanced cell sorting devices for laboratory research and clinical diagnostics. Founded in 2011, the company utilizes its patented Dielectric Spectroscopy (CDS) technology to enable label-free cell analysis, providing detailed insights at single-cell resolution. This technology supports various applications in biopharma and cell therapy by facilitating automated, quantitative assessments of samples and enhancing phenotypic drug discovery. Cytomos’ system is designed to scale across all upstream production stages, leveraging machine learning algorithms to analyze extensive data from individual cells, thus improving the efficiency of cell-based diagnostics and enabling researchers to optimize therapeutic dosing.

Chromacity Ltd. is a company based in Edinburgh, United Kingdom, that specializes in the development, manufacture, and distribution of wavelength tunable femtosecond lasers for various applications in life sciences and spectroscopy. The company's product lineup includes several advanced laser systems, such as the Spark 1030-nm and Spark-HP 1040-nm femtosecond lasers, which are designed for high performance and versatility. Additionally, Chromacity offers femtosecond optical parametric oscillators (OPOs), such as the Spark-OPO and Spark-ultra, which produce tunable femtosecond pulses across a broad range of wavelengths. The technology is built on robust, patent-pending fiber-laser innovations, providing reliable and user-friendly operation through an embedded web server. Chromacity also collaborates with systems manufacturers to supply custom OEM femtosecond and picosecond lasers tailored to specific engineering and materials processing needs. Founded in 2013 as a spin-out from Heriot-Watt University, the company leverages over 40 years of expertise in ultrafast lasers and serves clients in North America, the United Kingdom, the Middle East, and beyond.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.

Adaptix specializes in advancing diagnostic imaging technology by transforming traditional planar X-ray systems into more effective and accessible solutions. The company focuses on integrating low-dose 3D capabilities, known as digital tomosynthesis, into X-ray equipment while ensuring portability and affordability. This innovation aims to enhance patient access to critical imaging technologies and improve diagnostic accuracy for prevalent health issues such as cardiovascular and pulmonary diseases, lung cancer, and osteoporosis. Adaptix's approach utilizes a new Flat Panel X-ray source, developed using semiconductor technology, which allows for multiple low-dose acquisitions rather than relying on a single high-dose capture. This shift not only provides more comprehensive imaging data but also results in significant cost savings compared to current bulky and expensive X-ray systems. Adaptix’s technology is designed to be incorporated into products by X-ray system manufacturers, who will ultimately ensure compliance with regulatory standards.

M Squared Lasers is a manufacturer of advanced lasers and photonic instruments designed to enhance capabilities, reliability, and usability across various industrial and scientific sectors. With over twenty years of experience, the company specializes in harnessing the power of light to drive innovation and facilitate cross-sector partnerships. Its product offerings cater to diverse industries, including manufacturing, oil and gas, space technology, and healthcare. M Squared's technology plays a significant role in breakthroughs in fields such as dementia research, cancer diagnosis, and whiskey maturation. By providing cutting-edge solutions, M Squared Lasers aims to address complex challenges and accelerate advancements in multiple applications.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.

Adaptix specializes in advancing diagnostic imaging technology by transforming traditional planar X-ray systems into more effective and accessible solutions. The company focuses on integrating low-dose 3D capabilities, known as digital tomosynthesis, into X-ray equipment while ensuring portability and affordability. This innovation aims to enhance patient access to critical imaging technologies and improve diagnostic accuracy for prevalent health issues such as cardiovascular and pulmonary diseases, lung cancer, and osteoporosis. Adaptix's approach utilizes a new Flat Panel X-ray source, developed using semiconductor technology, which allows for multiple low-dose acquisitions rather than relying on a single high-dose capture. This shift not only provides more comprehensive imaging data but also results in significant cost savings compared to current bulky and expensive X-ray systems. Adaptix’s technology is designed to be incorporated into products by X-ray system manufacturers, who will ultimately ensure compliance with regulatory standards.

Chromacity Ltd. is a company based in Edinburgh, United Kingdom, that specializes in the development, manufacture, and distribution of wavelength tunable femtosecond lasers for various applications in life sciences and spectroscopy. The company's product lineup includes several advanced laser systems, such as the Spark 1030-nm and Spark-HP 1040-nm femtosecond lasers, which are designed for high performance and versatility. Additionally, Chromacity offers femtosecond optical parametric oscillators (OPOs), such as the Spark-OPO and Spark-ultra, which produce tunable femtosecond pulses across a broad range of wavelengths. The technology is built on robust, patent-pending fiber-laser innovations, providing reliable and user-friendly operation through an embedded web server. Chromacity also collaborates with systems manufacturers to supply custom OEM femtosecond and picosecond lasers tailored to specific engineering and materials processing needs. Founded in 2013 as a spin-out from Heriot-Watt University, the company leverages over 40 years of expertise in ultrafast lasers and serves clients in North America, the United Kingdom, the Middle East, and beyond.

Adaptix specializes in advancing diagnostic imaging technology by transforming traditional planar X-ray systems into more effective and accessible solutions. The company focuses on integrating low-dose 3D capabilities, known as digital tomosynthesis, into X-ray equipment while ensuring portability and affordability. This innovation aims to enhance patient access to critical imaging technologies and improve diagnostic accuracy for prevalent health issues such as cardiovascular and pulmonary diseases, lung cancer, and osteoporosis. Adaptix's approach utilizes a new Flat Panel X-ray source, developed using semiconductor technology, which allows for multiple low-dose acquisitions rather than relying on a single high-dose capture. This shift not only provides more comprehensive imaging data but also results in significant cost savings compared to current bulky and expensive X-ray systems. Adaptix’s technology is designed to be incorporated into products by X-ray system manufacturers, who will ultimately ensure compliance with regulatory standards.

Lamellar Biomedical Ltd. is a biotechnology company based in Bellshill, United Kingdom, focused on developing and commercializing medical devices and pharmaceuticals that leverage mimetics of extra-alveolar lamellar bodies. The company offers Lamellasomes, a synthetic product designed to replicate the functions of lamellar bodies, primarily targeting respiratory diseases such as cystic fibrosis, as well as conditions like dry eye disease and radiotherapy-induced xerostomia. Established in June 2007, Lamellar Biomedical acquired the intellectual property rights to this innovative technology, which aims to improve treatment outcomes through anti-infective properties that enhance antibiotic efficacy and facilitate the delivery of genetic material for pulmonary disease therapies. The company's efforts are directed towards providing transformative solutions for complex and rare respiratory conditions.

MOFgen Ltd is a pioneering company that specializes in the commercialization of metal-organic frameworks (MOFs) for medical and therapeutic applications. Originating as a spin-out from the University of St Andrews, the company leverages patented technology developed by renowned porous material scientist Prof Russell Morris. MOFgen focuses on designing, manufacturing, and formulating MOFs to create innovative solutions for healthcare challenges. Its products include powdery solids with microscopic pores capable of incorporating antibacterial agents, wound healing compounds, and anti-thrombotic substances. These advanced coatings for medical devices aim to enhance patient care by reducing infection rates and minimizing the need for prolonged hospital stays. Through collaboration with various partners, MOFgen is committed to developing tailored solutions for issues such as healthcare-associated infections, bacterial resistance, chronic wounds, and arterial access.

Clear Surgical Ltd is a medical device company founded in 2013 and based in Larbert, United Kingdom. The company specializes in designing, manufacturing, and selling innovative devices for surgical use. Its notable products include The Oplight, an LED-based device that illuminates surgical cavities to enhance visibility during procedures, and Cannulated Reduction Forceps, which integrate a guidance system to facilitate optimal implant placement in orthopedic surgeries. Clear Surgical aims to improve surgical outcomes and efficiency in healthcare delivery through its advanced technologies.

Chromacity Ltd. is a company based in Edinburgh, United Kingdom, that specializes in the development, manufacture, and distribution of wavelength tunable femtosecond lasers for various applications in life sciences and spectroscopy. The company's product lineup includes several advanced laser systems, such as the Spark 1030-nm and Spark-HP 1040-nm femtosecond lasers, which are designed for high performance and versatility. Additionally, Chromacity offers femtosecond optical parametric oscillators (OPOs), such as the Spark-OPO and Spark-ultra, which produce tunable femtosecond pulses across a broad range of wavelengths. The technology is built on robust, patent-pending fiber-laser innovations, providing reliable and user-friendly operation through an embedded web server. Chromacity also collaborates with systems manufacturers to supply custom OEM femtosecond and picosecond lasers tailored to specific engineering and materials processing needs. Founded in 2013 as a spin-out from Heriot-Watt University, the company leverages over 40 years of expertise in ultrafast lasers and serves clients in North America, the United Kingdom, the Middle East, and beyond.

Taragenyx Ltd. is an orthopedic biotechnology company based in Glasgow, United Kingdom, specializing in the development of self-healing implant technologies aimed at enhancing the body's natural repair processes. Established in 2010, the company focuses on a range of applications within spine, trauma, extremities, and biologics. Taragenyx creates innovative therapeutic implants, incorporating bio-passive, bio-active, and bio-regenerative coatings that integrate active pharmaceuticals and biologics into the implant surface. This technology allows for localized release of compounds post-operatively, which can accelerate bone growth, promote faster healing, and reduce the risk of infection and pain. The company’s products are specifically designed to address limb-threatening surgical complications, thereby improving patient outcomes in orthopedic and dental procedures.

Clear Surgical Ltd is a medical device company founded in 2013 and based in Larbert, United Kingdom. The company specializes in designing, manufacturing, and selling innovative devices for surgical use. Its notable products include The Oplight, an LED-based device that illuminates surgical cavities to enhance visibility during procedures, and Cannulated Reduction Forceps, which integrate a guidance system to facilitate optimal implant placement in orthopedic surgeries. Clear Surgical aims to improve surgical outcomes and efficiency in healthcare delivery through its advanced technologies.

Sirakoss is a medical device company based in Scotland that specializes in the development of synthetic bone graft substitutes. The company focuses on creating innovative solutions for trauma, spine, craniomaxillofacial, and dental applications. Sirakoss is advancing its proprietary MaxSi™ Graft technology, which is available in granular and putty forms. This technology is designed to facilitate the fusion of bones, addressing various conditions including congenital and degenerative issues. By providing effective treatment options, Sirakoss aims to enhance patient recovery and support a return to healthy lifestyles.

UWI Technology Limited, founded in 2009 and based in Edinburgh, United Kingdom, specializes in innovative label solutions designed to enhance product safety and consumption. The company's flagship product, UWI Label, is an elapsed time indicator that informs users when a jar or container was first opened and tracks how long it has remained open. This technology is particularly useful in various sectors, including pharmaceuticals, medical devices, industrial applications, food and beverages, and cosmetics. By providing critical information about product usage and expiration, UWI Technology aims to mitigate the risks associated with using outdated or potentially harmful products, thereby promoting safety and efficiency in consumption.

Ocutec Ltd. is a company based in Bellshill, United Kingdom, that specializes in designing, developing, and marketing polyethylene glycol-based contact lens materials for vision correction and eye care. Founded in 2001, Ocutec leverages the materials science expertise of Professor Neil Graham and his team at the University of Strathclyde to create innovative solutions. The company focuses on developing both thermoset and thermoplastic contact lens materials that utilize polyethylene glycol (PEG) polymer chemistry. This technology facilitates step-growth polymerization, resulting in hydrated lens surfaces that mimic the extracellular matrix. As a result, Ocutec's lenses enhance tear film stability, promote ocular health, and provide improved comfort for users, allowing them the freedom to see without spectacles.

Clear Surgical Ltd is a medical device company founded in 2013 and based in Larbert, United Kingdom. The company specializes in designing, manufacturing, and selling innovative devices for surgical use. Its notable products include The Oplight, an LED-based device that illuminates surgical cavities to enhance visibility during procedures, and Cannulated Reduction Forceps, which integrate a guidance system to facilitate optimal implant placement in orthopedic surgeries. Clear Surgical aims to improve surgical outcomes and efficiency in healthcare delivery through its advanced technologies.

DYSIS Medical Ltd. is a medical device company based in Edinburgh, United Kingdom, specializing in imaging systems for the non-invasive, in-vivo detection of cancerous and pre-cancerous lesions. The company has developed the DYSIS Colposcope, a digital device that assesses the aceto-whitening reaction and presents the findings in an intuitive map format. In addition to the colposcope, DYSIS Medical offers a range of accessories, including both disposable and reusable specula, diathermy loops, and coagulation balls, as well as software for image data management and development of the DYSISmap. Founded in 2002 and rebranded in 2011, DYSIS Medical aims to improve early detection of cancers, potentially addressing significant healthcare challenges globally. The company maintains sales offices in Tampa, Florida; Edinburgh; and Athens, Greece.

Taragenyx Ltd. is an orthopedic biotechnology company based in Glasgow, United Kingdom, specializing in the development of self-healing implant technologies aimed at enhancing the body's natural repair processes. Established in 2010, the company focuses on a range of applications within spine, trauma, extremities, and biologics. Taragenyx creates innovative therapeutic implants, incorporating bio-passive, bio-active, and bio-regenerative coatings that integrate active pharmaceuticals and biologics into the implant surface. This technology allows for localized release of compounds post-operatively, which can accelerate bone growth, promote faster healing, and reduce the risk of infection and pain. The company’s products are specifically designed to address limb-threatening surgical complications, thereby improving patient outcomes in orthopedic and dental procedures.

Lamellar Biomedical Ltd. is a biotechnology company based in Bellshill, United Kingdom, focused on developing and commercializing medical devices and pharmaceuticals that leverage mimetics of extra-alveolar lamellar bodies. The company offers Lamellasomes, a synthetic product designed to replicate the functions of lamellar bodies, primarily targeting respiratory diseases such as cystic fibrosis, as well as conditions like dry eye disease and radiotherapy-induced xerostomia. Established in June 2007, Lamellar Biomedical acquired the intellectual property rights to this innovative technology, which aims to improve treatment outcomes through anti-infective properties that enhance antibiotic efficacy and facilitate the delivery of genetic material for pulmonary disease therapies. The company's efforts are directed towards providing transformative solutions for complex and rare respiratory conditions.

UWI Technology Limited, founded in 2009 and based in Edinburgh, United Kingdom, specializes in innovative label solutions designed to enhance product safety and consumption. The company's flagship product, UWI Label, is an elapsed time indicator that informs users when a jar or container was first opened and tracks how long it has remained open. This technology is particularly useful in various sectors, including pharmaceuticals, medical devices, industrial applications, food and beverages, and cosmetics. By providing critical information about product usage and expiration, UWI Technology aims to mitigate the risks associated with using outdated or potentially harmful products, thereby promoting safety and efficiency in consumption.

mLED Limited, based in Glasgow, United Kingdom, specializes in the development and manufacture of gallium nitride micropixellated light-emitting diode (LED) arrays. The company focuses on micro-LED technology, providing system integrators with the tools necessary to create prototype and production units for a variety of applications, including industrial, medical, and commercial sectors. mLED's technology enables the production of application-specific light patterns tailored to specific pixel layouts and addressing, as well as custom-specified wavelengths and both continuous pulsed and modulated light patterns.

mLED Limited, based in Glasgow, United Kingdom, specializes in the development and manufacture of gallium nitride micropixellated light-emitting diode (LED) arrays. The company focuses on micro-LED technology, providing system integrators with the tools necessary to create prototype and production units for a variety of applications, including industrial, medical, and commercial sectors. mLED's technology enables the production of application-specific light patterns tailored to specific pixel layouts and addressing, as well as custom-specified wavelengths and both continuous pulsed and modulated light patterns.

Ocutec Ltd. is a company based in Bellshill, United Kingdom, that specializes in designing, developing, and marketing polyethylene glycol-based contact lens materials for vision correction and eye care. Founded in 2001, Ocutec leverages the materials science expertise of Professor Neil Graham and his team at the University of Strathclyde to create innovative solutions. The company focuses on developing both thermoset and thermoplastic contact lens materials that utilize polyethylene glycol (PEG) polymer chemistry. This technology facilitates step-growth polymerization, resulting in hydrated lens surfaces that mimic the extracellular matrix. As a result, Ocutec's lenses enhance tear film stability, promote ocular health, and provide improved comfort for users, allowing them the freedom to see without spectacles.

Ocutec Ltd. is a company based in Bellshill, United Kingdom, that specializes in designing, developing, and marketing polyethylene glycol-based contact lens materials for vision correction and eye care. Founded in 2001, Ocutec leverages the materials science expertise of Professor Neil Graham and his team at the University of Strathclyde to create innovative solutions. The company focuses on developing both thermoset and thermoplastic contact lens materials that utilize polyethylene glycol (PEG) polymer chemistry. This technology facilitates step-growth polymerization, resulting in hydrated lens surfaces that mimic the extracellular matrix. As a result, Ocutec's lenses enhance tear film stability, promote ocular health, and provide improved comfort for users, allowing them the freedom to see without spectacles.

B1 Medical develops and manufactures medical devices for orthopedics. B1 Medical develops and markets products such as soft tissue monitoring, fracture fixation and small joint prothesis products.